Conservin compositions

• US 6,031,076 A
• Filed: 01/05/1998
• Issued: 02/29/2000
• Est. Priority Date: 07/30/1996
• Status: Expired due to Fees

• Current Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: Falb, Dean A., Gimeno, Carlos J.
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): Kaufman, Claire M.
• Application Number:
  US09/002,832
• Time in Patent Office: 785 Days
• Field of Search: 530/350, 530/300, 530/402, 514/2, 514/12, 435/69.1, 536/23.1, 536/23.5, 536/23.4
• US Class Current: 530/350
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/495 Transforming growth factor [TGF]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The present invention relates to the discovery of novel conservin genes and polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.

Claims

1. An isolated polypeptide which is encoded by the nucleotide sequence of SEQ ID NO:

1, 2, 4, or 5.

2. The isolated polypeptide of claim 1, wherein said polypeptide is encoded by the nucleotide sequence of SEQ ID NO:

1.

3. A composition comprising the polypeptide of claim 2, and a pharmaceutically acceptable carrier.

4. A fusion polypeptide comprising the polypeptide of claim 2, and a heterologous polypeptide.

5. The isolated polypeptide of claim 2, further comprising a label.

6. The isolated polypeptide of claim 1, wherein said polypeptide is encoded by the nucleotide sequence of SEQ ID NO:

2.

7. A composition comprising the polypeptide of claim 6, and a pharmaceutically acceptable carrier.

8. A fusion polypeptide comprising the polypeptide of claim 6, and a heterologous polypeptide.

9. The isolated polypeptide of claim 6, further comprising a label.

10. The isolated polypeptide of claim 1, wherein said polypeptide is encoded by the nucleotide sequence of SEQ ID NO:

4.

11. A composition comprising the polypeptide of claim 10, and a pharmaceutically acceptable carrier.

12. A fusion polypeptide comprising the polypeptide of claim 10, and a heterologous polypeptide.

13. The isolated polypeptide of claim 10, further comprising a label.

14. The isolated polypeptide of claim 1, wherein said polypeptide is encoded by the nucleotide sequence of SEQ ID NO:

5.

15. A composition comprising the polypeptide of claim 14, and a pharmaceutically acceptable carrier.

16. A fusion polypeptide comprising the polypeptide of claim 14, and a heterologous polypeptide.

17. The isolated polypeptide of claim 14, further comprising a label.

18. A composition comprising the polypeptide of claim 1, and a pharmaceutically acceptable carrier.

19. A fusion polypeptide comprising the polypeptide of claim 1, and a heterologous polypeptide.

20. The isolated polypeptide of claim 1, further comprising a label.

21. An isolated polypeptide which is encoded by the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048.

22. A composition comprising the polypeptide of claim 21, and a pharmaceutically acceptable carrier.

23. A fusion polypeptide comprising the polypeptide of claim 21, and a heterologous polypeptide.

24. The isolated polypeptide of claim 21, further comprising a label.

25. An isolated polypeptide which is encoded by the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98049.

26. A composition comprising the polypeptide of claim 25, and a pharmaceutically acceptable carrier.

27. A fusion polypeptide comprising the polypeptide of claim 25, and a heterologous polypeptide.

28. The isolated polypeptide of claim 25, further comprising a label.

29. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:

3.

30. A composition comprising the polypeptide of claim 29, and a pharmaceutically acceptable carrier.

31. A fusion polypeptide comprising the polypeptide of claim 29, and a heterologous polypeptide.

32. The isolated polypeptide of claim 29, further comprising a label.

33. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:

6.

34. A composition comprising the polypeptide of claim 33, and a pharmaceutically acceptable carrier.

35. A fusion polypeptide comprising the polypeptide of claim 33, and a heterologous polypeptide.

36. The isolated polypeptide of claim 33, further comprising a label.

37. An isolated polypeptide which is at least 92.5% identical to the amino acid sequence of SEQ ID NO:

3 or 6 and which binds in a yeast two hybrid assay with the polypeptide encoded by the fchd534 gene deposited with NRRL as Accession Number B-21459.

38. A composition comprising the polypeptide of claim 37, and a pharmaceutically acceptable carrier.

39. A fusion polypeptide comprising the polypeptide of claim 37, and a heterologous polypeptide.

40. The isolated polypeptide of claim 37, further comprising a label.

41. An isolated polypeptide which is at least 92.5% identical to the amino acid sequence encoded by the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049 and which binds in a yeast two hybrid assay with the polypeptide encoded by the fchd534 gene deposited with NRRL as Accession Number B-21459.

42. A composition comprising the polypeptide of claim 41, and a pharmaceutically acceptable carrier.

43. A fusion polypeptide comprising the polypeptide of claim 41, and a heterologous polypeptide.

44. The isolated polypeptide of claim 41, further comprising a label.

45. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:

3.

46. A composition comprising the polypeptide of claim 45, and a pharmaceutically acceptable carrier.

47. A fusion polypeptide comprising the polypeptide of claim 45, and a heterologous polypeptide.

48. The isolated polypeptide of claim 45, further comprising a label.

49. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:

6.

50. A composition comprising the polypeptide of claim 49, and a pharmaceutically acceptable carrier.

51. A fusion polypeptide comprising the polypeptide of claim 49, and a heterologous polypeptide.

52. The isolated polypeptide of claim 49, further comprising a label.